Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Abstract

The objective of the present trial was to compare the efficacy, safety, and tolerability of moxifloxacin (400 mg) given intravenously (i.v.) once daily followed by oral moxifloxacin (400 mg) for 7 to 14 days with the efficacy, safety, and tolerability of co-amoxiclav (1.2 g) administered by i.v. infusion three times a day followed by oral co-amoxiclav (625… (More)

Topics

8 Figures and Tables

Cite this paper

@article{Finch2002RandomizedCT, title={Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.}, author={Roger G. Finch and David Schuermann and O. Collins and R. F. Kubin and James J McGivern and Herman J Bobbaers and Jos{\'e} Luis Izquierdo and Paul Nikolaides and F. O. Ogundare and Regina Raz and Paul D Zuck and Gerd G Hoeffken}, journal={Antimicrobial agents and chemotherapy}, year={2002}, volume={46 6}, pages={1746-54} }